RC220
Research
Racura links bisantrene’s active isomer to MYC gene silencing
Racura Oncology has presented preclinical data identifying (E,E)-bisantrene as the major active isomer responsible for stabilizing the MYC G-quadruplex and reducing MYC…
ResearchRacura Cleared to Raise RC220 Dose to 100 mg/m2 in HARNESS-1 Lung Cancer Trial
The Safety Review Committee for Racura Oncology's HARNESS-1 trial has cleared the drug RC220 to move to the next planned dose level of 100 mg/m2, after finding no…